Clinical treatment score post-5 years and survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age
ExET should be considered in premenopausal and postmenopausal breast cancer patients with high CTS5 levels.
Authors
- Seho Park (ORCID: https://orcid.org/0000-0001-8089-2755)
- Seung Hye Yang
- Jee Ye Kim (ORCID: https://orcid.org/0000-0003-3936-4410)
- Byeong‐Woo Park (ORCID: https://orcid.org/0000-0003-1353-2607)
- Hyung Seok Park (ORCID: https://orcid.org/0000-0001-5322-6036)
- Suk Jun Lee (ORCID: https://orcid.org/0000-0003-3839-5071)
- Jee Hyun Ahn (ORCID: https://orcid.org/0000-0003-4176-3277)
- Seung Il Kim (ORCID: https://orcid.org/0000-0001-9673-2748)
Institutions
- Yonsei University (KR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1007/s10549-025-07679-6
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00